Quick Answer
Cocrystal Pharma, Inc. reported Diluted EPS of $0.78 per share (loss) for fiscal year 2025.
Cocrystal Pharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.78 | +54.7% |
| 2024 | -$1.72 | +8.0% |
| 2023 | -$1.87 | +60.8% |
| 2022 | -$4.77 | -15800.0% |
| 2017 | -$0.03 | +99.1% |
| 2016 | -$3.30 | -37.5% |
| 2015 | -$2.40 | -23900.0% |
| 2014 | -$0.01 | +85.7% |
| 2013 | -$0.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.19 | +61.2% | +5.0% |
| June 30, 2025 | -$0.20 | +62.3% | +13.0% |
| March 31, 2025 | -$0.23 | +41.0% | +53.1% |
| September 30, 2024 | -$0.49 | -19.5% | +7.5% |
| June 30, 2024 | -$0.53 | -29.3% | -35.9% |
| March 31, 2024 | -$0.39 | +39.1% | +4.9% |
| September 30, 2023 | -$0.41 | +41.4% | +0.0% |
| June 30, 2023 | -$0.41 | +86.3% | +35.9% |
- Cocrystal Pharma, Inc. showed an increase of +54.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2013–2025 period, Cocrystal Pharma, Inc.’s diluted eps has declined by 1014.3% (from $0.07 per share (loss) to $0.78 per share (loss)).
- The most recent figure is from Cocrystal Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: